JPRN-UMIN000011210已完成未知
Randomized Phase II trial on conventional administration (continuous administration for 2 weeks followed by one week interval) and alternate-day administration of adjuvant chemotherapy drug TS-1 in patients who underwent complete resection of non-small cell lung cancer. - conventional administration (continuous administration for 2 weeks followed by one week interval) vs alternate-day administration
Teikyo University school of Medicine0 个研究点目标入组 80 人开始时间: 2013年8月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Cases in which apparent interstitial pneumonia or pulmonary fibrosis is observed by routine chest radiograph or chest CT. 2) Cases which require drainage of accumulated pleural fluid, ascetic fluid and effusion. 3) Cases with synchronous or metachronous active double cancer or multiple cancer. 4) Cases with complications which are hard to control (such as cardiac disease, liver disease, severe diabetes and hemorrhage). 5) Cases accompanied with diarrhea (watery diarrhea). 6) Patients who are pregnant or nursing or women who might be pregnant. 7) Male patients planning to have a child. 8) Patients with prior drug hypersenstitivity. 9) Patients with history of severe hypersensitivity to TS-1 components. 10) Patients who are undergoing a treatment with other fluorinated pyrimidine-type anti-tumor drugs. 11) Patients in which the administration of TS-1 is prohibited. 12) Patients who are undergoing a treatment with warfarin potassium, phenytoin or flucytosine. 13) Other cases which are determined to be unsuitable to this study
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 clinical trial investigating GS-5806 in adult Lung Transplant (LT) recipients with Respiratory Syncytial Virus (RSV) InfectioRespiratory Syncytial Virus (RSV) InfectionMedDRA version: 18.1Level: LLTClassification code 10039247Term: RSV infectionSystem Organ Class: 100000004862EUCTR2015-002287-16-BEGilead Sciences, Inc.60
已完成
2 期
A Phase 2b, Randomized, Controlled Trial Evaluating GS 5806 in Lung Transplant (LT) Recipients with Respiratory Syncytial Virus (RSV) InfectioNL-OMON43361Gilead Sciences2
进行中（未招募）
1 期
A Phase 2 clinical trial investigating GS-5806 in adult Lung Transplant (LT) recipients with Respiratory Syncytial Virus (RSV) InfectioRespiratory Syncytial Virus (RSV) InfectionMedDRA version: 19.0Level: LLTClassification code 10039247Term: RSV infectionSystem Organ Class: 100000004862EUCTR2015-002287-16-ATGilead Sciences, Inc.60
进行中（未招募）
1 期
A Phase 2 clinical trial investigating GS-5806 in adult Lung Transplant (LT) recipients with Respiratory Syncytial Virus (RSV) InfectioRespiratory Syncytial Virus (RSV) InfectionMedDRA version: 19.0 Level: LLT Classification code 10039247 Term: RSV infection System Organ Class: 100000004862EUCTR2015-002287-16-GBGilead Sciences, Inc.61
进行中（未招募）
1 期
A Phase 2 clinical trial investigating GS-5806 in adult Lung Transplant (LT) recipients with Respiratory Syncytial Virus (RSV) InfectioRespiratory Syncytial Virus (RSV) InfectionMedDRA version: 19.0Level: LLTClassification code 10039247Term: RSV infectionSystem Organ Class: 100000004862EUCTR2015-002287-16-NLGilead Sciences, Inc.60